Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-11
2008-03-11
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S367000
Reexamination Certificate
active
07342017
ABSTRACT:
A compound of formula:(wherein X, R1, R3, R4, and R5are disclosed herein) or a pharmaceutically acceptable salt thereof (a “Thiadiazolylpiperazine Compound”), pharmaceutical compositions comprising a Thiadiazolylpiperazine Compound, and methods for treating or preventing, e.g., pain, depression and anxiety, in a patient comprising administering to a patient in need thereof an effective amount of a Thiadiazolylpiperazine Compound are disclosed.
REFERENCES:
patent: 5039680 (1991-08-01), Imperato et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5198459 (1993-03-01), Imperato et al.
patent: 5232934 (1993-08-01), Downs
patent: 5556837 (1996-09-01), Nestler et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5762925 (1998-06-01), Sagen
patent: 6109269 (2000-08-01), Rise et al.
patent: 6204284 (2001-03-01), Beer et al.
patent: 6239267 (2001-05-01), Duckworth et al.
patent: 6335180 (2002-01-01), Julius et al.
patent: 6406908 (2002-06-01), McIntyre et al.
patent: 6974818 (2005-12-01), Kyle et al.
patent: 2003/0153596 (2003-08-01), Suh et al.
patent: 2003/0158188 (2003-08-01), Lee et al.
patent: 2003/0158198 (2003-08-01), Lee et al.
patent: WO 02/08221 (2002-01-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 03/022809 (2003-03-01), None
patent: WO 03/062209 (2003-07-01), None
patent: WO 03/068749 (2003-08-01), None
Berkow et al., “The Merck Manual of Medical Information,” pp. 345-350, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 352-355, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 496-500, 1997.
Berkow et al., “The Merck manual of Medical Information,” pp. 525-526, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 528-530, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 530-532, 1997.
Berkow et al., “The Merck Manual of Medical Information,” pp. 631-634, 1997.
Bevan et al., “Vanilloid Receptors: Pivotal Molecules in Nocciception,” Curent Opinions in CPNS Investigational Drugs, 2(2):178-85, 2000.
Chiamulera et al., “Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant rice,” Nature Neuroscience, 4(9):873-874, 2001.
Cooke, “Glycopyrrolate in bladder dysfunction,” SA Medical J., 63:3, 1983.
Dogrul et al., “Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR5) antagonist, in experimental neuropathic pain in rats,” Neuroscience Letters, 292(2):115-118, 2000.
Foley, “Pain,” Cecil Textbook of Medicine, pp. 100-107, 1996.
Goodman and Gillman's The Pharmaceutical Basis of Therapeutics, 506, 901-915 (J. Hardman and L. Limbird eds., 9thed., 1996).
Herzog et al., “Urinary Incontinence: Medical and Psychosocial Aspects,” Annu. Rev. Gerontol. Geriatr., 9:74-119, 1989.
Levin et al., “Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder,” J. Urology, 128:396-398, 1982.
Mirakhur et al., “Glycopyrrolate: pharmacology and clinical use,” Anaesthesia, 38:1195-1204, 1983.
Ossowska et al., “Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats,” Neuropharmacology, 41:413-420, 2001.
Resnick, “Urinary Incontinence,”Lancet, 346:94-99, 1995.
Szallash et al., “Vanilloid (Capsaicin) Receptors and Mechanisma,” Pharmacology Reviews, 51(2):159-211, 1999.
Tatarczynska et al., “Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist,” British J. Pharmacology, 132(7):1423-1430, 2001.
Toth et al., “Design of a high-affinity competitive antagonist of the vanilloid receptor selective for the calcium entry-liked receptor population,” Mol. Pharmacol., 65(2):282-91, 2004.
Walker et al., “Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 redeptors in models of acute, persistent and chronic pain,” Neuropharmacology, 40:1-9, 2000.
Wang et al., “High affinity antagonists of the vanilloid receptor,” Mol. Pharmacol., 62(4):947-56, 2002.
Wein, “Pharmacology of Incontinence,” Urologic Clinics of North America, 22(3):557-577, 1995.
Wermuth et al.,“Glossary of terms use in Medicinal Chemistry,” IUPAC Recommendations, retrieved from <http:/www.chem.qmw.ac.uk/iupac/medchem/ah.html>, 1998.
Will et al., “Novel allosteric antagonists shed light on mglu5receptors and CNS disorders,” Trends in Pharmacological Sciences, 22(7):331-337, 2001.
Wrigglesworth et al., “Capsicin-like Agonists,” Drugs of the Future, 23(5):531-38, 1998.
Kyle Donald J.
Sun Qun
Euro-Celtique S.A.
Jones Day
Sackey Ebenezer
Wilson James O.
LandOfFree
1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2796684